Clinical Trials on PARP Inhibitor for Esophageal Squamous Cell Carcinoma

Total 3751 results

Chongqing University Cancer Hospital

Not yet recruiting

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

PARP Inhibitor for Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

Esophageal Squamous Cell Carcinoma (ESCC) | PD-1 Inhibitors

China
Shanghai Runshi Pharmaceutical Technology Co., Ltd

Not yet recruiting

A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma

Advanced Oesophageal Squamous Cell Carcinoma
Sichuan University

Recruiting

Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC) | Neoantigen-loaded Dendritic Cell Vaccine | Immune Checkpoint Inhibitors (ICIs)

China
Tang-Du Hospital

Recruiting

Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

Chemotherapy | Esophageal Squamous Cell Carcinoma | PD-1 Inhibitor | Neoadjuvent

China
Imperial College London
Imperial College Healthcare NHS Trust

Recruiting

Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms (ViSON)

Oesophageal Squamous Cell Carcinoma | Oesophageal Cancer

United Kingdom
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer (RAMONA)

Esophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer Nos

Germany
Nanfang Hospital of Southern Medical University

Recruiting

Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody

Esophageal Squamous Cell Carcinoma | PD-1 Inhibitor

China
Shanghai Zhongshan Hospital

Recruiting

NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma (NATION1907II)

Oesophageal Squamous Cell Carcinoma

China
Sanofi
Merck Sharp & Dohme LLC

Terminated

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Oesophageal Adenocarcinoma | Oesophageal Squamous Cell Carcinoma

Korea, Republic of, Belgium, Italy, United States, Chile, China, France, Netherlands, Spain
Federation Francophone de Cancerologie Digestive
Shire; Servier

Completed

Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma (OESIRI)

Squamous Cell Carcinoma

France
Sun Yat-sen University

Active, not recruiting

Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)

Esophageal Cancer | Esophageal Squamous Cell Carcinoma | Oesophageal Cancer

China
Royal Marsden NHS Foundation Trust

Completed

Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus

Oesophageal Carcinoma

United Kingdom
Biotech Pharmaceutical Co., Ltd.

Unknown

Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinomas

China
Shanghai Chest Hospital

Not yet recruiting

Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy (SINCERE)

Esophageal Squamous Cell Carcinomas
Fuzhou General Hospital

Recruiting

Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery

Esophageal Squamous Cell Carcinomas

China
Chinese University of Hong Kong

Recruiting

The Microbiome of Oesophageal Squamous Cell Carcinoma

Esophageal Cancer | Microbial Colonization

Hong Kong
Zhejiang University

Active, not recruiting

a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC Study (ANACIIRE-1)

The Neoadjuvant Treatment for Resectable Esophageal Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...
Akeso Pharmaceuticals, Inc.

Not yet recruiting

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

Metastatic Esophageal Squamous Cell Carcinoma | Unresectable Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

Esophageal Squamous Cell Carcinomas

China
Academisch Medisch Centrum - Universiteit van Amsterdam...
University Medical Center Groningen; UMC Utrecht; Erasmus Medical Center; Catharina... and other collaborators

Recruiting

TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY (TAPESTRY)

Carcinoma, Squamous Cell | Oesophageal Cancer

Netherlands
Hebei Medical University Fourth Hospital

Unknown

A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma

Refractory or Metastatic Esophageal Squamous Cell Carcinoma

China
National Cancer Institute (NCI)

Terminated

Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy

Esophageal Cancer | Esophageal Neoplasms | Esophageal Adenocarcinoma | Squamous Cell Carcinoma | Esophageal Squamous Cell Cancer

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Advanced or Metastatic Esophageal Squamous Cell Carcinoma

France, Spain, Denmark, Korea, Republic of, Argentina, Thailand, United Kingdom, Turkey, Czechia, Singapore, Hungary, Ukraine, Poland, Russian Federation, Taiwan, Italy, Kenya, Brazil
Bristol-Myers Squibb

Completed

A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

Esophageal Squamous Cell Carcinoma

United Kingdom
Peking University

Unknown

Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial

Advanced Esophageal Squamous Carcinoma

China
Shanghai Chest Hospital

Not yet recruiting

Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE) (RICE)

Chemotherapy | Immunotherapy | Concurrent Chemoradiotherapy | Esophageal Squamous Cell Carcinomas
Fujian Medical University Union Hospital

Not yet recruiting

Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection

Esophageal Squamous Cell Carcinoma Thoracic Stage II | Esophageal Squamous Cell Carcinoma Thoracic Stage III | Esophageal Squamous Cell Carcinoma Thoracic Stage IV

China
The First Affiliated Hospital of Henan University...
Luoyang Central Hospital; Nanyang Central Hospital; Sanmenxia Central Hospital; Military 150 Hospital and other collaborators

Active, not recruiting

Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer (CRTCOESC)

Stage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Henan University...

Unknown

Different Cycles of Cisplatin-5-fluorouracil for the Chemoradiotherapy of Esophageal Squamous Cancer (PFCRTESC)

Stage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell Carcinoma

China
Jiangsu Cancer Institute & Hospital

Recruiting

Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus (SCALE-2)

Locally Advanced Esophageal Carcinoma

China
The First People's Hospital of Changzhou

Not yet recruiting

SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC

Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Henan University...

Unknown

Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy (DCECRT)

Stage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell Carcinoma

China
Shanghai Zhongshan Hospital
Zhejiang Cancer Hospital; Sun Yat-sen University; Cancer Institute and Hospital... and other collaborators

Recruiting

Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC (iCROSS)

Esophageal Squamous Cell Carcinoma Stage II | Esophageal Squamous Cell Carcinoma Stage III

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (JUPITER06)

Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy

China
The First Affiliated Hospital of Henan University...

Unknown

Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer

Stage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell Carcinoma | Stage I Esophageal Adenocarcinoma | Stage II Esophageal Adenocarcinoma | Stage III Esophageal Adenocarcinoma | Stage I Esophageal Squamous Cell Carcinoma

China
National Cancer Center, Japan
Ono Pharmaceutical Co. Ltd; Fiverings Co., Ltd.

Active, not recruiting

A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma

Japan
Sun Yat-sen University

Completed

Improve the Treatment of Thoracic Esophageal Cancer

Thoracic Esophageal Squamous Cell Carcinoma

China
Shanghai Chest Hospital

Recruiting

Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Cancer | Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Squamous Cell Carcinoma

China
National Taiwan University Hospital

Enrolling by invitation

The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma

Metastatic Esophageal Squamous Cell Carcinoma | Esophageal Tumor

Taiwan
The First Affiliated Hospital of Henan University...

Completed

Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy

Stage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell Carcinoma

China
CStone Pharmaceuticals

Active, not recruiting

A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma

Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

China
BeiGene

Active, not recruiting

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Cancer | Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma by AJCC V8 Stage

China, Taiwan, Thailand, Korea, Republic of
Shanghai Chest Hospital

Recruiting

A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)

Esophageal Squamous Cell Carcinoma (ESCC)

China
Nanfang Hospital, Southern Medical University

Recruiting

Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma (ANSWER)

Advanced Esophageal Squamous Cell Carcinoma

China
Peking University

Not yet recruiting

The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Thoracic Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

Resectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University

Recruiting

Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma

Thoracic Esophageal Squamous Cell Carcinoma

China
BeiGene

Completed

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)

Spain, United States, China, Belgium, France, Taiwan, Japan, Germany, United Kingdom, Korea, Republic of, Italy

Clinical Trials on PARP Inhibitor for Esophageal Squamous Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations